373P Synchronous or metachronous esophageal cancer is associated with a lower survival rate in patients with head and neck squamous cell carcinoma

Most head and neck squamous cell carcinoma patients are elderly, with few younger than 40 years. Controversy exists in the literature regarding outcomes for younger patients. The goal of this research project was to compare baseline features and outcomes for young patients (≤40 years), middle-aged patients (41–64 years), and old patients (≥65 years). To investigate the relationship between age and important presenting features and outcomes, 1160 recently diagnosed patients first treated at Washington University between 1980 and 1991 were identified from an existing database. Full 5-year survival information was available for 1030 patients (89%). Overall, the 5-year survival rate was 46% (478/1030); young patients (65%, 26/40) had a significantly better survival rate than middle-aged (52%, 292/566) or old patients (38%, 160/424) (χ2 = 24.5; P = 0.001). Survival was also related to smoking, comorbidity, primary site, TNM stage, and nodal disease. Age remained a significant factor even after we controlled for these other factors. Young patients developed fewer recurrent and new primary tumors. We conclude that young patients have a much better overall prognosis than older patients. The reasons for this difference are unclear, but it appears that the impact of age goes beyond an actuarial effect.

Download Full-text

Analysis of the Prognosis and Therapeutic Value of the CXC Chemokine Family in Head and Neck Squamous Cell Carcinoma

Frontiers in Oncology ◽

10.3389/fonc.2020.570736 ◽

2021 ◽

Vol 10 ◽

Author(s):

Yongchao Li ◽

Tinghui Wu ◽

Shujuan Gong ◽

Hangzheng Zhou ◽

Lufei Yu ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Survival Rate ◽

Cell Carcinoma ◽

Head And Neck ◽

Clinical Data ◽

Squamous Cell ◽

Neck Squamous Cell Carcinoma ◽

Mrna Levels ◽

Tissue Samples ◽

Cxc Chemokine

The CXC chemokines belong to a family which includes 17 different CXC members. Accumulating evidence suggests that CXC chemokines regulate tumor cell proliferation, invasion, and metastasis in various types of cancers by influencing the tumor microenvironment. The different expression profiles and specific function of each CXC chemokine in head and neck squamous cell carcinoma (HNSCC) are not yet clarified. In our work, we analyzed the altered expression, interaction network, and clinical data of CXC chemokines in patients with HNSCC by using the following: the Oncomine dataset, cBioPortal, Metascape, String analysis, GEPIA, and the Kaplan–Meier plotter. The transcriptional level analysis suggested that the mRNA levels of CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL8, CXCL9, CXCL10, CXCL11, and CXCL13 increased in HNSCC tissue samples when compared to the control tissue samples. The expression levels of CXCL9, CXCL10, CXCL11, CXCL12, and CXCL14 were associated with various tumor stages in HNSCC. Clinical data analysis showed that high transcription levels of CXCL2, CXCL3, and CXCL12, were linked with low relapse-free survival (RFS) in HNSCC patients. On the other hand, high CXCL14 levels predicted high RFS outcomes in HNSCC patients. Meanwhile, increased gene transcription levels of CXCL9, CXCL10, CXCL13, CXCL14, and CXCL17 were associated with a higher overall survival (OS) advantage in HNSCC patients, while high levels of CXCL1, and CXCL8 were associated with poor OS in all HNSCC patients. This study implied that CXCL1, CXCL2, CXCL3, CXCL8, and CXCL12 could be used as prognosis markers to identify low survival rate subgroups of patients with HNSCC as well as be potential suitable therapeutic targets for HNSCC patients. Additionally, CXCL9, CXCL10, CXCL13, CXCL14, and CXCL17 could be used as functional prognosis biomarkers to identify better survival rate subgroups of patients with HNSCC.

Download Full-text

Decoding the Genetic Alterations in PRAME Gene Family and Its Association with Head and Neck Squamous Cell Carcinoma

Journal of Pharmaceutical Research International ◽

10.9734/jpri/2020/v32i2030733 ◽

2020 ◽

pp. 93-102

Author(s):

J. Dhivyadharshini ◽

A. S. Smiline Girija ◽

A. Paramasivam ◽

J. Vijayashree Priyadharsini

Keyword(s):

Gene Expression ◽

Squamous Cell Carcinoma ◽

Survival Rate ◽

Gene Family ◽

Cell Carcinoma ◽

Head And Neck ◽

Expression Profile ◽

Squamous Cell ◽

Genetic Alterations ◽

Neck Squamous Cell Carcinoma

Head and neck squamous cell carcinoma (HNSCC) is the most common form of cancer with an incidence rate greater in male than in female. Advancements in molecular diagnostics have identified several pathways which can have a direct or indirect role in the development and progression of HNSCC. The PRAME (PReferentially Antigen expressed in MElanoma) gene family is yet another group of genes which has been recently implicated in HNSCC. The present study aims to identify the genetic alterations, the pattern of gene expression and the consequence of mutations in the PRAME family of genes in HNSCC patients. Several databases such as cBioportal, gnomAD, IMutant, PROVEAN were used to assess genetic alterations. The alterations included deep deletions, amplification, inframe, missense, truncating mutations. The gene showing the highest frequency of alteration (PRAME - 3%) was further assessed for its gene expression profile using the UALCAN database. The expression profile relative to normal samples was found to be significantly higher in HNSCC patients (p = 1.11 x 10-16). Further, the survival curve based on high and low/medium expression of the PRAME gene was assessed by Kaplan-Meier method. The analysis revealed a significant difference in the survival rate of patients with high and low/medicum level expression (0.0095). In addition, the high level expression was found to be associated with poor survival rate in HNSCC patients compared to those exhibiting low and medium level expression. In conclusion the study provides insights into the putative association of genes of the PRAME family with HNSCC. The preliminary results have to be further validated using experimental procedures.

Download Full-text

Resection of secondary pulmonary malignancies in head and neck cancer patients

The Journal of Laryngology & Otology ◽

10.1017/s0022215110001064 ◽

2010 ◽

Vol 124 (12) ◽

pp. 1278-1283 ◽

Cited By ~ 2

Author(s):

T W Geurts ◽

H M Klomp ◽

S A Burgers ◽

H van Tinteren ◽

B Y Roukema ◽

...

Keyword(s):

Overall Survival ◽

Squamous Cell Carcinoma ◽

Survival Rate ◽

Confidence Interval ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Lung Lesion ◽

Neck Squamous Cell Carcinoma ◽

Pulmonary Cancer

AbstractBackground:This study aimed to evaluate a single institute's experience with resection of metachronous pulmonary malignancy in patients treated for squamous cell carcinoma of the head and neck.Methods:Sixty-three consecutive patients treated curatively for head and neck squamous cell carcinoma underwent surgical resection of malignant lung lesions. Survival was estimated and potential prognostic factors investigated.Results:The median overall survival for the total group was 22.2 months. Fifty-one patients (81 per cent) had one lung lesion, while the remainder had multiple lesions (range, two to seven). In the 63 patients, 35 lobectomies, 4 pneumonectomies and 24 wedge resections were performed. For patients with pulmonary squamous cell carcinoma (n = 52), the three-year survival rate was 35 per cent (95 per cent confidence interval, 22–48); for patients with resected adenocarcinoma (n = 10), it was 50 per cent (95 per cent confidence interval, 18–75). The overall five-year survival rate was 30 per cent (95 per cent confidence interval, 19–42).Conclusion:In patients treated curatively for head and neck squamous cell carcinoma, resection of secondary pulmonary cancer is associated with favourable long term overall survival, especially for patients with adenocarcinoma lesions.

Download Full-text

Deleted in Esophageal Cancer 1(DEC1) Is Down-Regulated and Contributes to Migration in Head and Neck Squamous Cell Carcinoma Cell Lines

ORL ◽

10.1159/000320997 ◽

2011 ◽

Vol 73 (1) ◽

pp. 17-23 ◽

Cited By ~ 2

Author(s):

Yasuomi Kunimoto ◽

Seiji Nakano ◽

Hideyuki Kataoka ◽

Yutaka Shimada ◽

Mitsuo Oshimura ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Esophageal Cancer ◽

Cell Carcinoma ◽

Head And Neck ◽

Cell Lines ◽

Squamous Cell ◽

Carcinoma Cell ◽

Neck Squamous Cell Carcinoma ◽

Squamous Cell Carcinoma Cell ◽

Carcinoma Cell Lines

Download Full-text

The Applications of Radiomics for Predicting Survival Rate of Patients with Head and Neck Squamous Cell Carcinoma (HNSCC)

Journal of Magnetics ◽

10.4283/jmag.2020.25.4.587 ◽

2020 ◽

Vol 25 (4) ◽

pp. 587-594

Author(s):

Sang Won Park ◽

Payam Hosseinzadeh Kasani ◽

Na Young Yeo ◽

Gab-Jung Kim ◽

Se-Jong Yoo ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Survival Rate ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Neck Squamous Cell Carcinoma

Download Full-text

CORRELATION OF P21 EXPRESSION IN HEAD AND NECK SQUAMOUS CELL CARCINOMA WITH CLINICOPATHOLOGIC AND PROGNOSTIC PARAMETERS

Journal of Cancer & Allied Specialties ◽

10.37029/jcas.v1i2.33 ◽

2015 ◽

Vol 1 (2) ◽

Cited By ~ 1

Author(s):

Safana Sadaf ◽

Asif Loya ◽

Sajid Mushtaq ◽

Noreen Akhter ◽

Raza Hussain ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Survival Rate ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Tertiary Care ◽

Nodal Metastasis ◽

Neck Squamous Cell Carcinoma ◽

Depth Of Invasion ◽

Increased Risk

Purpose: Head and neck tumours include tumours of nose, paranasal sinuses, oropharynx, larynx and mouth. Squamous cell carcinoma (SCC) is the most common head and neck malignant tumour which accounts for 90% of head and neck malignant tumours. p21 is an important immunohistochemical marker which has signi cant role in predicting prognosis of head and neck SCC (HNSCC). Increased p21 expression in HNSCC is associated with bad prognosis in terms of increased risk of nodal metastasis, increased rate of recurrence and decreased survival rate. The purpose of this study was to evaluate the expression of p21 in HNSCC with various clinicopathologic and prognostic parametres. Materials and Methods: A total of 110 patients (n = 110) of HNSCC (oral cavity n = 98 and laryngeal tumours n = 12) were included in the study which were diagnosed and treated between January 2008 and January 2011 at a tertiary care centre in Pakistan. Mean age was 51 years (age range 15–78). 65 (59%) were male and 45 (41%) were female. Tumours were classi ed as p21 positive when ≥10% tumour cells were immunoreactive for p21. p21 expression was noted and correlated with T-stage, nodal metastasis, perineural and depth of invasion, recurrence and 2-year survival rate. Results: Of 110 cases, p21-positive cases were 88 (80%) compared to 22 (20%) negative. T1–T2 tumours with p21 expression were 59 (67.04%) while 17 cases (77.27%) had negative for p21 (P = 0.44). Amongst T3–T4, 29 cases showed p21 expression (32.96%) while 5 cases (22.73%) were negative (P = 0.44). Nodal metastasis was seen in 51 cases (57.95%) with p21 positivity as compared to 4 cases (18.8%) with no p21 expression (P = 0.0015). Perineural invasion was seen in 15 carcinomas (17.04%) having p21 positivity and 1 case (4.54%) with p21 negativity (P = 0.18). 48 cases (54.54%) had depth of invasion >1 cm with positive p21 as compared to 4 cases (18.18%) without (P value = 0.0035). 39 cases (44.31%) showed recurrence along with p21 expression while 3 cases (13.63%) showed recurrence without (P = 0.0076). 2-year survival rate was 56.81% (n = 88) in p21 positive cases, whereas it was 90.90% (n = 20) those with negative p21 (P = 0.0026). Conclusion: Positive p21 expression in HNSCC correlates with intermediate grade, late stage, increased nodal metastasis, tumour recurrence and decreased survival. p21 should be considered as an important prognostic and predictive marker in HNSCC to detect tumours at early stage and to improve therapy and prognosis. Key words: Head and neck squamous cell carcinoma, lymph node metastasis, p21, recurrence, survival rate

Download Full-text